Nonserious Infections. Should There Be Cause for Serious Concerns?

Rheumatic Disease Clinics of North America

Volumn 38, Issue 4, 2012, Pages 707-725

  Dao, Kathryn H ^a   Herbert, Morley ^b   Habal, Nadia ^c   Cush, John J ^a  

^a BAYLOR RESEARCH INSTITUTE   (United States)

^b MEDICAL CITY DALLAS HOSPITAL   (United States)

^c Northern Virginia Arthritis   (United States)

Author keywords

Adalimumab; Anti TNF; Etanercept; Infliximab; Nonserious infections; Rheumatoid arthritis; Safety

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO;

ANKYLOSING SPONDYLITIS; CONTROLLED STUDY; CROHN DISEASE; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; FLU LIKE SYNDROME; HIGH RISK PATIENT; HUMAN; INFECTION; INFECTION RISK; LOW DRUG DOSE; META ANALYSIS; NONSERIOUS INFECTION; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS; RHINITIS; RISK ASSESSMENT; SERIOUS INFECTIOUS EVENT; SINUSITIS; SKIN INFECTION; SOFT TISSUE INFECTION; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOGLOBULIN G; OPPORTUNISTIC INFECTIONS; RECEPTORS, TUMOR NECROSIS FACTOR; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84868357446     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2012.08.016     Document Type: Review

References (60)

1. Dixon W.G., Watson K., Lunt M., et al. Rates of serious infection, including site specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-TNF necrosis factor therapy. Arthritis Rheum 2006, 54(8):2368-2376.
2. Wolfe F., Caplan L., Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia. Arthritis Rheum 2006, 54(2):628-634.
3. Listing J., Strangfeld A., Kary S., et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005, 52(11):3403-3412.
4. Doran M., Crowson C., Pond G., et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population based study. Arthritis Rheum 2002, 46(9):2287-2293.
5. Bongartz T., Sutton A., Sweeting M., et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295(19):2275-2285.
6. Fernandez-Nebro A., Irigoyen M., Urena I., et al. Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naïve rheumatoid arthritis. J Rheumatol 2007, 34(12):2334-2342.
7. Kroesen S., Widmer A.F., Tyndall A., et al. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-a therapy. Rheumatology 2003, 42:617-621.
8. Poole M.D., Portugal L.G. Treatment of rhinosinusitis in the outpatient setting. Am J Med 2005, 118:45S-50S.
9. Fendrick A.M., Monto A.S., Nightingale B., et al. The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch Intern Med 2003, 163:487-494.
10. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 2002, 113(Suppl 1A):5S-13S.
11. Keating K.N., Perfetto E.M., Subedi P. Economic burden of uncomplicated urinary tract infections: direct, indirect and intangible costs. Expert Rev Pharmacoecon Outcomes Res 2005, 5(4):457-466.
12. Molinari N.A., Ortega-Sanchez I.R., Messonnier M.L., et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007, 25(27):5086-5096.
13. Pallin D.J., Egan D.J., Pelletier A.J., et al. Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus. Ann Emerg Med 2008, 51(3):291-298. [Epub 2008 Jan 28].
14. Saurat J.H., Stingl G., Dubertret L., et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008, 158:558-566. CHAMPION Study Investigators.
15. Menter A., Tyring S.K., Gordon K., et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008, 58:106-115.
16. Genovese M.C., Mease P.J., Thomson G.T., et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol 2007, 34:1040-1050. M02-570 Study Group.
17. van der Heijde D., Kivitz A., Schiff M.H., et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006, 54:2136-2146. ATLAS Study Group.
18. Mease P.J., Gladman D.D., Ritchlin C.T., et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005, 52:3279-3289. Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group.
19. Keystone E.C., Kavanaugh A.F., Sharp J.T., et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004, 50:1400-1411.
20. Van de Putte L.B., Atkins C., Malaise M., et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004, 63:508-516.
21. Weinblatt M.E., Keystone E.C., Furst D.E., et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003, 48:35-45.
22. Van de Putte L.B., Rau R., Breedveld F.C., et al. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis 2003, 62:1168-1177.
23. Furst D.E., Schiff M.H., Fleischmann R.M., et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003, 30:2563-2571.
24. Breedveld F.C., Weisman M.H., Kavanaugh A.F., et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006, 54:26-37.
25. Emery P., Breedveld F.C., Hall S., et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008, 372(9636):375-382.
26. Weisman M.H., Paulus H.E., Burch F.X., et al. A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases. Rheumatology (Oxford) 2007, 46:1122-1125.
27. Tyring S., Gordon K.B., Poulin Y., et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007, 143:719-726.
28. Van der Heijde D., Da Silva J.C., Dougados M., et al. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis 2006, 65:1572-1577. Etanercept Study 314 Investigators.
29. Tyring S., Gottlieb A., Papp K., et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006, 367:29-35.
30. van der Heijde D., Klareskog L., Rodriguez-Valverde V., et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006, 54:1063-1074. TEMPO Study Investigators.
31. Papp K.A., Tyring S., Lahfa M., et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005, 152:1304-1312. Etanercept Psoriasis Study Group.
32. Keystone E.C., Schiff M.H., Kremer J.M., et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004, 50:353-363.
33. Mease P.J., Kivitz A.J., Burch F.X., et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004, 50:2264-2272.
34. Leonardi C.L., Powers J.L., Matheson R.T., et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003, 349:2014-2022. Etanercept Psoriasis Study Group.
35. Davis J.C., van der Heijde D., Braun J., et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003, 48:3230-3236. Enbrel Ankylosing Spondylitis Study Group.
36. Gottlieb A.B., Matheson R.T., Lowe N., et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003, 139:1627-1632.
37. Bathon J.M., Martin R.W., Fleischmann R.M., et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000, 343:1586-1593.
38. Moreland L.W., Schiff M.H., Baumgartner S.W., et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999, 130:478-486.
39. Westhovens R., Yocum D., Han J., et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum 2006, 54:1075-1086. START Study Group.
40. Reich K., Nestle F.O., Papp K., et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005, 366:1367-1374. EXPRESS study investigators.
41. Kavanaugh A., Krueger G.G., Beutler A., et al. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 2007, 66:498-505. IMPACT 2 Study Group.
42. Antoni C.E., Kavanaugh A., Kirkham B., et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005, 52:1227-1236.
43. van der Heijde D., Dijkmans B., Geusens P., et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005, 52:582-591. Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group.
44. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis Act I & II. N Engl J Med 2005, 353:2462-2476.
45. St Clair E.W., van der Heijde D.M., Smolen J.S., et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004, 50:3432-3443.
46. Maini R., St Clair E.W., Breedveld F., et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999, 354:1932-1939.
47. Present D.H., Rutgeerts P., Targan S., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999, 340:1398-1405.
48. Maini R.N., Breedveld F.C., Kalden J.R., et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998, 41:1552-1563.
49. Keystone E.C., Ware C.F. Tumor necrosis factor and anti-tumor necrosis factor therapies. J Rheumatol Suppl 2010, 85:27-39.
50. Dixon W.G., Kezouh A., Bernatsky S., et al. The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study. Ann Rheum Dis 2011, 70(6):956-960.
51. Strangfeld A., Listing J., Herzer P., et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009, 301(7):737-744.
52. Tubach F., Salmon D., Ravaud P., et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French research axed on tolerance of biotherapies registry. Arthritis Rheum 2009, 60(7):1884-1894.
53. Wallis R.S., Broder M.S., Wong J.Y., et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004, 38(9):1261-1265.
54. Salmon-Ceron D., Tubach F., Lortholary O., et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 2011, 70(4):616-623.
55. Mitoma H., Horiuchi T., Tsukamoto H., et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor -expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum 2008, 58:1248-1257.
56. Leombruno J.P., Einarson T.R., Keystone E.C. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009, 68(7):1136-1145.
57. Askling J., Fored C.M., Brandt L., et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA-patients treated with TNF- antagonists. Ann Rheum Dis 2007, 66(10):1339-1344.
58. Solomon D.H., Lunt M., Schneeweiss S. The risk of infection associated with tumor necrosis factor alpha antagonists: making sense of epidemiologic evidence. Arthritis Rheum 2008, 58(4):919-928.
59. Du Pan S.M., Dehler S., Ciurea A., et al. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 2009, 61(5):560-568.
60. Grijalva C.G., Chen L., Delzell E., et al. Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011, 306(21):2331-2339.